- Home
- PTN vs PYPD Comparison
PTN vs PYPD Comparison
Compare PTN & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTN
- PYPD
- Stock Information
- Founded
- PTN 1986
- PYPD 2008
- Country
- PTN United States
- PYPD Israel
- Employees
- PTN N/A
- PYPD N/A
- Industry
- PTN Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- PTN Health Care
- PYPD Health Care
- Exchange
- PTN Nasdaq
- PYPD Nasdaq
- Market Cap
- PTN N/A
- PYPD 26.7M
- IPO Year
- PTN 1993
- PYPD 2020
- Fundamental
- Price
- PTN $0.09
- PYPD $2.72
- Analyst Decision
- PTN Strong Buy
- PYPD Strong Buy
- Analyst Count
- PTN 1
- PYPD 2
- Target Price
- PTN $7.00
- PYPD $10.50
- AVG Volume (30 Days)
- PTN 6.6M
- PYPD 15.4K
- Earning Date
- PTN 05-14-2025
- PYPD 05-14-2025
- Dividend Yield
- PTN N/A
- PYPD N/A
- EPS Growth
- PTN N/A
- PYPD N/A
- EPS
- PTN N/A
- PYPD N/A
- Revenue
- PTN $350,000.00
- PYPD N/A
- Revenue This Year
- PTN N/A
- PYPD N/A
- Revenue Next Year
- PTN N/A
- PYPD N/A
- P/E Ratio
- PTN N/A
- PYPD N/A
- Revenue Growth
- PTN N/A
- PYPD N/A
- 52 Week Low
- PTN $0.09
- PYPD $2.30
- 52 Week High
- PTN $2.48
- PYPD $4.75
- Technical
- Relative Strength Index (RSI)
- PTN 15.19
- PYPD 49.90
- Support Level
- PTN $0.18
- PYPD $2.71
- Resistance Level
- PTN $0.22
- PYPD $3.25
- Average True Range (ATR)
- PTN 0.02
- PYPD 0.15
- MACD
- PTN 0.01
- PYPD 0.02
- Stochastic Oscillator
- PTN 4.53
- PYPD 33.75
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.